Login to Your Account



Clinic Roundup


Thursday, October 13, 2011
Intellikine Inc., of La Jolla, Calif., said it treated the first patient in a Phase I study of INKN1117, a selective, orally available, small-molecule inhibitor of the PI3K-alpha isoform, in patients with advanced solid malignancies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription